English EN Spanish ES French FR Chinese (Simplified) ZH-CN
Print Friendly, PDF & Email

NCT/Study#

NCT03930953 /

CC-99282-NHL-001

A Phase 1, Multi-Center, Open-Label Study To Assess The Safety, Pharmacokinetics, And Preliminary Efficacy Of An Orally Available Small Molecule, CC-99282, Alone And In Combination With Rituximab In Subjects With Relapsed Or Refractory Non-Hodgkin Lymphomas (R/R NHL)

DISEASE GROUP:
Lymphoma
current phase:
Phase I
STUDY STATUS:
Accepting Patients
Location:
Hackensack, NJ
For More information: